Stereotaxis announced FDA submission for EMAGIN™ 5F, a catheter aimed at enhancing robotic navigation in endovascular procedures.
Quiver AI Summary
Stereotaxis, a leader in surgical robotics, has announced the FDA submission for its first robotically navigated catheter, the EMAGIN™ 5F, aiming to expand Robotic Magnetic Navigation into broader endovascular procedures. This 5-French catheter is designed for intricate navigation through the vascular system, utilizing magnetic fields for improved precision and safety in minimally invasive treatments for conditions like stroke and cardiovascular diseases. The company expects to file for European CE Mark clearance soon and plans to launch the catheter later this year. Key medical experts have expressed optimism about the technology’s potential to enhance clinical interventions. Stereotaxis aims to be a multi-specialty robotics leader, leveraging this platform technology across various medical fields.
Potential Positives
- Stereotaxis submitted a 510(k) application for its innovative EMAGIN™ 5F robotic catheter, marking a significant step in expanding Robotic Magnetic Navigation's applications in endovascular interventions.
- The EMAGIN brand represents a comprehensive portfolio of robotic catheters and wires, highlighting the company's commitment to innovation and growth in the surgical robotics market.
- Statements from leading medical professionals indicate strong clinical interest and potential for the EMAGIN 5F to enhance the safety, precision, and efficiency of complex procedures, which can lead to better patient outcomes.
- The anticipated launch of the EMAGIN 5F in the latter half of the year, following approvals, positions Stereotaxis for potential revenue growth and expanded market presence in the healthcare industry.
Potential Negatives
- The press release includes a significant disclaimer about forward-looking statements, indicating uncertainty regarding future performance and potential risks associated with regulatory approvals and market acceptance.
- There is no guarantee of successful commercialization or revenue generation from the EMAGIN 5F due to external contingencies, which may impact investor confidence.
- The reliance on third-party vendors and potential changes in healthcare policy could present challenges in the company's operations and market strategy.
FAQ
What is the EMAGIN 5F catheter?
The EMAGIN 5F is Stereotaxis' first robotically navigated catheter designed for enhanced endovascular procedures.
What technology does the EMAGIN brand utilize?
The EMAGIN brand uses Robotic Magnetic Navigation to enhance the accuracy and safety of navigating complex vascular anatomy.
How does the EMAGIN 5F benefit patients?
It improves the efficiency and safety of minimally invasive procedures for conditions like stroke, cancer, and cardiovascular disease.
When does Stereotaxis expect to launch EMAGIN 5F?
Stereotaxis anticipates launching EMAGIN 5F in the second half of 2025, pending regulatory approvals.
What is Stereotaxis' mission?
Stereotaxis aims to develop robotic systems that enhance patient care and expand access to minimally invasive therapies in medicine.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STXS Hedge Fund Activity
We have seen 44 institutional investors add shares of $STXS stock to their portfolio, and 28 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 382,412 shares (+12.4%) to their portfolio in Q4 2024, for an estimated $871,899
- REDMILE GROUP, LLC removed 308,754 shares (-14.6%) from their portfolio in Q4 2024, for an estimated $703,959
- LAGODA INVESTMENT MANAGEMENT, L.P. added 295,700 shares (+7.7%) to their portfolio in Q4 2024, for an estimated $674,196
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 197,165 shares (-14.0%) from their portfolio in Q4 2024, for an estimated $449,536
- TRAYNOR CAPITAL MANAGEMENT, INC. added 160,509 shares (+inf%) to their portfolio in Q4 2024, for an estimated $365,960
- GOLDMAN SACHS GROUP INC added 152,056 shares (+154.3%) to their portfolio in Q4 2024, for an estimated $346,687
- WARBERG ASSET MANAGEMENT LLC removed 144,860 shares (-71.5%) from their portfolio in Q4 2024, for an estimated $330,280
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field.
EMAGIN™ 5F is the first in a family of robotically navigated endovascular devices being developed by Stereotaxis. The EMAGIN brand – short for Endovascular Magnetic Intervention – will encompass a comprehensive portfolio of robotic catheters and wires. EMAGIN 5F is a catheter guide with a 5-French diameter used to navigate tortuous venous and arterial vasculature. Robotic navigation of the catheter directly from the distal tip, using precise magnetic fields, is designed to enable efficient and safe navigation to otherwise difficult-to-reach vascular anatomy. It expands the established benefits of Robotic Magnetic Navigation into multiple new clinical applications including minimally-invasive procedures used to treat stroke, cancer, and cardiovascular disease.
“Robotic Magnetic Navigation offers significant promise to address clinical challenges we face in the neurointerventional field by enabling safe and rapid navigation through tortuous vasculature,” said Prof. Timo Krings, Chair of the Division of Neurointerventional Radiology at Beth Israel Lahey Health in Boston and Professor of Radiology at UMass TH Chan School of Medicine. “I’m excited by the opportunity to help pioneer this technology, evaluate and demonstrate its clinical value, and explore entirely new applications that may become possible. Our field is uniquely poised to benefit from robotics and we look forward to advancing the technology and clinical science over the coming years.”
“The evolution of robotics in interventional cardiology is inevitable and will be of significant benefit to patients, physicians, and healthcare systems,” said Dr. Kalpa De Silva, Interventional Cardiologist at St Thomas’ Hospital, Guy's and St Thomas' NHS Foundation Trust in London. “I see significant promise in the use of the robotically-steered EMAGIN catheter to enhance the safety, precision, and efficiency of various challenging procedures including renal denervation and complex percutaneous coronary interventions. I look forward to helping pioneer this technology.”
Stereotaxis submitted a 510(k) application for EMAGIN 5F with the FDA and expects to submit the catheter for European CE Mark clearance this month. EMAGIN 5F was designed and is manufactured by Stereotaxis’ fully-owned subsidiary Access Point Technologies in Minnesota. Stereotaxis expects to launch EMAGIN 5F following anticipated approvals in the second half of this year, with a focus on demonstrating clinical value for Robotic Magnetic Navigation in multiple new endovascular applications.
“Robotic Magnetic Navigation is a platform technology that can offer significant clinical value across endovascular medicine,” said David Fischel, Stereotaxis Chairman and CEO. “We are thrilled to announce this milestone as we embark on the journey to make Stereotaxis a multi-specialty robotics leader advancing clinical care in interventional cardiology, radiology and neurology.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
